Related Experiment Video
Updated: Jan 21, 2026

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth
Published on: August 11, 2011
Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study
Gian Paolo Fadini1, Michael Feher2,3, Troels Krarup Hansen4
1Department of Medicine, Division of Metabolic Diseases, University of Padova, Padova, Italy.
Switching to insulin degludec significantly reduced hypoglycemia events in patients with type 1 and type 2 diabetes. This basal insulin also improved glycemic control and treatment satisfaction in real-world settings.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Observational data on insulin degludec (degludec) and hypoglycemia events are limited.
- Evaluating degludec's safety and effectiveness in routine care is crucial for diabetes management.
Purpose of the Study:
- To assess the safety and effectiveness of degludec in patients with type 1 diabetes (T1D) or type 2 diabetes (T2D) switching from other basal insulins.
- To analyze hypoglycemia rates, glycemic control, and treatment satisfaction post-switch to degludec.
Main Methods:
- A multinational, prospective, observational, single-arm study was conducted.
- Included insulin-treated T1D (n=556) and T2D (n=611) patients switching to degludec.
- Data collected over a 12-month follow-up period, comparing to a 4-week baseline.
Main Results:
- Significantly lower rates of overall, severe, and nocturnal hypoglycemia were observed in T1D patients switching to degludec.
- T2D patients also showed significantly reduced overall, nonsevere, and nocturnal hypoglycemia rates.
- Improvements in HbA1c, fasting plasma glucose, and treatment satisfaction were noted in both T1D and T2D groups.
Conclusions:
- Switching to degludec in routine clinical practice is associated with significantly reduced hypoglycemia.
- Insulin degludec demonstrates effectiveness in improving glycemic control and patient satisfaction.
- These findings support the use of degludec for basal insulin therapy in T1D and T2D.
More Related Videos
08:22Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion
Published on: March 20, 2017
08:45Epigenetic Conversion as a Safe and Simple Method to Obtain Insulin-secreting Cells from Adult Skin Fibroblasts
Published on: March 18, 2016
Related Concept Videos
Hypoglycemia and Glucagon
Switching of BJT
Cut-off Mode ("Off" State): In this state, both the emitter-base and collector-base junctions are...
Reaction Rate
The mathematical representation of the change in the concentration of reactants and products, over time, is the rate...
Laminins are the Adhesive Proteins of Basal Lamina
In humans, the five forms of alpha chains are LAMA 1, LAMA 2, LAMA 3, LAMA 4, and LAMA 5. The four forms of beta chains are LAMB 1, LAMB 2, LAMB 3, and LAMB 4. The three forms of gamma...
Basal Lamina are the Specialized Form of ECM
Proteins...
Type IV Collagen of Basal Lamina
A type IV collagen molecule has six alpha chains which can...